Professor Allan Young is Chair of Mood Disorders and Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry, Psychology and Neuroscience at King’s College London, where he is also Head of School for Academic Psychiatry. The School of Academic Psychiatry is second in the world rankings for Psychiatry ( https://www.usnews.com/education/best-global-universities/psychiatry-psychology). He is the clinical academic lead in the Psychological Medicine and Integrated Care Clinical Academic Group in the South London and Maudsley NHS Trust, where he is also Consultant Psychiatrist and Head of the Affective Disorders Service. Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grants from several funding agencies and has over 700 peer-reviewed publications, including several books about psychopharmacology and affective disorders. He is editor of the Journal of Psychopharmacology and deputy editor of the British Journal of Psychiatry (Open). His H-index is 126 with over 88000 citations of his papers. Recent publications have been in the New England Journal of Medicine, JAMA Psychiatry, World Psychiatry and Lancet Psychiatry. Professor Young is a Clarivate Highly Cited Researcher: this highly anticipated annual list identifies researchers who demonstrated significant influence in their chosen field or fields through the publication of multiple highly cited papers during the last decade. Their names are drawn from the publications that rank in the top 1% by citations for field and publication year in the Web of Science™ citation index. Professor Young has current grant funding exceeding £30 million ( https://kclpure.kcl.ac.uk/portal/en/persons/allan-young(6bf03185-e533-4ac2-88ba-76349ba04ddf)/projects.html). He is past President of the International Society for Affective Disorders, past President of the British Association of Psychopharmacology and the Inaugural Chair of the Special Committee for Psychopharmacology of the Royal College of Psychiatrists. He is also a trustee of the patient and family charity Bipolar UK, and of the Drug Safety Research Unit (DSRU), which is internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.